In-silico network-based analysis of drugs used against COVID-19: Human well-being study

Attique, Zarlish; Ali, Ashaq; Hamza, Muhammad; Al‐Ghanim, Khalid A.; Mehmood, Azhar; Khan, Sajid; Ahmed, Zubair; Al-Mulhm, Norah; Rizwan, Muhammad; Munir, Anum; Al-Suliman, Emin; Farooq, Muhammad; Al‐Misned, Fahad A.; Mahboob, Shahid

doi:10.1016/j.sjbs.2021.01.006

Cited by 2 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the protein-protein interactions, we identified that physical interaction, co-expression, shared protein domains, pathway, co-localization, and genetic interaction were all included among the12 common proteins targeted by the ivermectin and the 6 selected antioxidants interacting with COVID-19. The results are comparable with another research studying another COVID-19 drug (Bevacizumab) that there were 61.00% of coexpression, 16.37% physical interaction, 10.78% of the pathway, 8.87% of prediction, 6.09% genetic interactions, 3.07% co-localization, and 3.88% of shared protein domains based on the analyses of protein-protein interactions [46].…”

Section: Pharmacogenomic Analyses Of Ivermectin and The Selected 6 An...supporting

confidence: 85%

Pharmacogenomic Landscape of Ivermectin and Selective Antioxidants: Exploring Gene Interplay in the Context of Long COVID

Yang,

Singh

2023

IJMS

View full text Add to dashboard Cite

COVID-19 pandemic has caused widespread panic and fear among the global population. As such, repurposing drugs are being used as viable therapeutic options due to the limited effective treatments for Long COVID symptoms. Ivermectin is one of the emerging repurposed drugs that has been shown effective to have antiviral effects in clinical trials. In addition, antioxidant compounds are also gaining attention due to their capabilities of reducing inflammation and severity of symptoms. Due to the absence of knowledge in pharmacogenomics and modes of actions in the human body for these compounds, this study aims to provide a pharmacogenomic profile for the combination of ivermectin and six selected antioxidants (epigallocatechin gallate (EGCG), curcumin, sesamin, anthocyanins, quercetin, and N-acetylcysteine (NAC)) as potentially effective regimens for long COVID symptoms. Results showed that there were 12 interacting genes found among the ivermectin, 6 antioxidants, and COVID-19. For network pharmacology, the 12 common interacting genes/proteins had the highest associations with Pertussis pathway, AGE-RAGE signaling pathway in diabetic complications, and colorectal cancer in the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Disease analyses also revealed that the top three relevant diseases with COVID-19 infections were diabetes mellitus, ischemia, reperfusion injury. We also identified 6 potential target microRNAs (miRNAs) of the 12 commonly curated genes used as molecular biomarkers for COVID-19 treatments. The established pharmacogenomic network, disease analyses, and identified miRNAs could facilitate developments of effective regimens for chronic sequelae of COVID-19 especially in this post-pandemic era. However, further studies and clinical trials are needed to substantiate the effectiveness and dosages for COVID-19 treatments.

show abstract

Section: Pharmacogenomic Analyses Of Ivermectin and The Selected 6 An...supporting

confidence: 85%

Pharmacogenomic Landscape of Ivermectin and Selective Antioxidants: Exploring Gene Interplay in the Context of Long COVID

Yang,

Singh

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…In light of this, we present our interactive dashboard, StarGazer, which aims to address these challenges by integrating three different datatypes (i.e., disease-target association, target druggability, and target protein-protein interaction) into a novel scoring system, utilizing real-time API calls and Python-based Streamlit technology. While these types of datasets have been used for numerous repositioning studies separately ( Liu et al, 2014 ; Khaladkar et al, 2017 ; Hermawan et al, 2020 ; Wijetunga et al, 2020 ; Adikusuma et al, 2021 ; Attique et al, 2021 ; Ghoussaini et al, 2021 ; Portelli et al, 2021 ; Tan et al, 2021 ; Varghese and Majumdar, 2022 ; Zhao et al, 2022 ), StarGazer represents the first ever integration of the PheWAS catalog, Open Targets, STRING and Pharos, all of which are well-curated, well-studied, open access databases. Furthermore, computational repositioning studies focus largely on singular diseases, phenotypes or drugs, but StarGazer is equipped for flexible investigation into any of the 1,844 phenotypes and traits within the dashboard.…”

Section: Introductionmentioning

confidence: 99%

StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit

et al. 2022

View full text Add to dashboard Cite

Target prioritization is essential for drug discovery and repositioning. Applying computational methods to analyze and process multi-omics data to find new drug targets is a practical approach for achieving this. Despite an increasing number of methods for generating datasets such as genomics, phenomics, and proteomics, attempts to integrate and mine such datasets remain limited in scope. Developing hybrid intelligence solutions that combine human intelligence in the scientific domain and disease biology with the ability to mine multiple databases simultaneously may help augment drug target discovery and identify novel drug-indication associations. We believe that integrating different data sources using a singular numerical scoring system in a hybrid intelligent framework could help to bridge these different omics layers and facilitate rapid drug target prioritization for studies in drug discovery, development or repositioning. Herein, we describe our prototype of the StarGazer pipeline which combines multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. StarGazer displays target prioritization scores for genes associated with 1844 phenotypic traits, and is available via https://github.com/AstraZeneca/StarGazer.

show abstract

In-silico network-based analysis of drugs used against COVID-19: Human well-being study

Cited by 2 publications

References 55 publications

Pharmacogenomic Landscape of Ivermectin and Selective Antioxidants: Exploring Gene Interplay in the Context of Long COVID

Pharmacogenomic Landscape of Ivermectin and Selective Antioxidants: Exploring Gene Interplay in the Context of Long COVID

StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit

Contact Info

Product

Resources

About